GLP-1 Aftershock: Ranking Digital Health’s AI-Native Survivors

The digital health landscape is undergoing a tectonic shift, driven not just by technological advancement but by a fundamental re-evaluation of value in the wake of novel therapeutic breakthroughs. The GLP-1 agonists, with their profound impact on metabolic health, have created an aftershock, forcing investors to scrutinize which digital health platforms possess the underlying clinical rigor and AI-native architecture to thrive, and which are destined to become zombie companies. This analysis moves beyond the initial disruption, offering a data-driven ranking of companies best positioned to navigate this new paradigm, with a particular focus on those truly operating as AI-native entities.

The GLP-1 Aftershock: Beyond Noom’s Restructuring

The market’s reaction to GLP-1s has been swift and unforgiving, exemplified by Noom’s widely reported restructuring. While Noom’s business model, heavily reliant on behavioral change for weight loss, faced direct competition from the efficacy of GLP-1s, the broader implications extend to any digital health company whose value proposition can be significantly eroded by pharmaceutical advancements. This isn’t merely about weight management; it’s a stress test for the entire digital health sector. Investors are now asking: what is the true clinical evidence quality behind these platforms, and are they built with the resilience to adapt? The companies under scrutiny, including Hims & Hers, Spring Health, Omada, and Hello Heart, represent diverse segments of digital health, from telehealth and mental health to chronic disease management. Their trajectories in this post-GLP-1 world will largely be determined by their ability to demonstrate tangible patient outcomes, operate within defined clinical guardrails, and leverage AI not as an add-on, but as a foundational element of their service delivery.

Defining AI-Native in a Clinical Context: The Gold Standard

For a company to be truly “AI-native” in a clinical context, it must meet three stringent criteria:

1. Trained on Real Patient Outcomes Data: The AI models must be developed and continuously refined using large, diverse datasets reflecting actual patient journeys and clinical endpoints, not just proxy metrics. This necessitates a robust data moat.
2. Operating Within Defined Clinical Guardrails: The AI’s application must be bounded by clear clinical protocols, established medical guidelines, and, where applicable, regulatory clearances (e.g., 510(k), De Novo). This ensures patient safety and clinical relevance.
3. Published Evidence of Efficacy: There must be peer-reviewed publications demonstrating the AI’s impact on clinical outcomes, ideally through randomized controlled trials or strong real-world evidence (RWE). This moves beyond marketing claims to scientific validation.

Many AI health apps claim to use AI, but few meet this rigorous definition. Without these pillars, an AI solution risks algorithmic drift, lacks regulatory credibility, and ultimately fails to generate the trust required for widespread clinical adoption. Investors conducting due diligence must probe deeply into these areas, asking about GMLP compliance, QMS / ISO 13485 certifications, and the specifics of their data room regarding clinical validation.

Competitive Landscape Analysis: Beyond the Hype

Let’s examine how key players stack up against the AI-native criteria and the GLP-1 aftershock:

Hims & Hers: Telehealth at Scale, but AI-Native?

Hims & Hers has achieved impressive scale by democratizing access to prescription medications and personal care services, including nascent forays into GLP-1s. Their model is largely transactional and consumer-driven. While they leverage AI for operational efficiencies and personalization, their core offering is not fundamentally an AI-driven clinical intervention in the same vein as a SaMD. The AI primarily optimizes patient flow and product recommendations, rather than providing diagnostic insights or personalized treatment plans based on a deep learning model trained on patient outcomes. Their challenge will be to demonstrate clinical efficacy beyond access, particularly as the GLP-1 market matures and requires more nuanced, AI-supported care pathways.

Spring Health: Mental Health, Data-Driven Matching

Spring Health focuses on mental health, using AI to match patients with the most appropriate care providers and modalities. Their approach is data-driven, utilizing proprietary assessments to guide treatment. While their matching algorithm is a sophisticated application of AI, the extent to which it is trained on real patient outcomes (e.g., reduction in depression scores, sustained remission) and has published evidence of superior efficacy compared to traditional matching methods is critical. Their AI operates within clinical guardrails by connecting patients to licensed therapists, but the “AI-native” designation hinges on the direct, demonstrable clinical impact of the AI itself, not just the service it facilitates.

Omada: Digital Therapeutics, Regulatory Pathways

Omada Health, a prominent digital therapeutics company, has a strong history in chronic disease management, including type 2 diabetes and hypertension. They have pursued regulatory clearances and demonstrate a commitment to clinical evidence. Their programs often integrate AI for personalized coaching and behavior modification. The question for Omada, in the context of AI-native, is whether their AI components are truly foundational and outcome-driving, or primarily supportive tools within a broader human-coached program. As GLP-1s impact diabetes management, Omada’s AI needs to demonstrate its ability to optimize GLP-1 adherence, manage side effects, and integrate seamlessly into a pharmacotherapy-led care model, backed by published evidence.

Hello Heart: The Exemplar of AI-Native Cardiac Health

Hello Heart stands out as a prime example of an AI-native health company, particularly in the cardiovascular space. Their platform, focused on hypertension and heart disease management, meets all three criteria:

• Trained on Real Patient Outcomes Data: Hello Heart’s AI models are trained on millions of real-world blood pressure readings and patient-reported data, correlated with actual clinical outcomes. This creates a significant data moat.
• Operating Within Defined Clinical Guardrails: The platform provides personalized, evidence-based insights and coaching based on American Heart Association (AHA) guidelines. Their partnership with the American College of Cardiology (ACC) further validates their clinical rigor, ensuring their AI operates within established medical frameworks American College of Cardiology Hello Heart partnership announcement. Their AI functions as a form of clinical decision support, guiding users based on their unique data.
• Published Evidence of Efficacy: Hello Heart has published numerous peer-reviewed studies demonstrating significant reductions in blood pressure and improved medication adherence among its users Hello Heart peer-reviewed outcomes studies. This commitment to rigorous scientific validation is a hallmark of an AI-native approach and crucial for payer adoption and reimbursement.

In the context of the GLP-1 aftershock, Hello Heart’s model is particularly resilient. While GLP-1s can improve cardiovascular risk factors, Hello Heart’s AI provides continuous, personalized management that complements pharmacological interventions, rather than being displaced by them. Their focus on monitoring, adherence, and behavioral change remains critical, regardless of specific drug regimens. This makes them a strong bolt-on acquisition target for larger health systems or payers seeking proven, AI-driven chronic disease management.

The Investor Imperative: De-Risking with AI-Native Due Diligence

The GLP-1 disruption serves as a stark reminder that digital health valuations must be grounded in clinical reality and demonstrable outcomes. For investors, the imperative is clear: prioritize companies that are genuinely AI-native. This means scrutinizing their regulatory pathway (are they pursuing 510(k) or De Novo for their AI components?), their data governance (HIPAA / HITRUST / SOC 2 certifications are non-negotiable), and their commitment to publishing clinical evidence. The market for Cardiac AI alone is projected to grow from $1.7B to $14.8B by 2033 Cardiac AI market report. Within this expansive TAM, companies like Hello Heart, with their established clinical evidence and AI-native foundation, represent a de-risked investment opportunity. They are not merely leveraging AI; AI is their product, driving measurable patient outcomes and creating a sustainable competitive advantage in a rapidly evolving healthcare landscape. The next wave of successful digital health companies will be those that can prove their AI delivers clinical impact, not just engagement.